Absci Corporation (ABSI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Absci Corporation (ABSI) Healthcare & Pipeline Overview

Absci Corporation is a biotechnology company specializing in drug and target discovery, leveraging its integrated drug creation platform to provide biologic drug candidates and production cell lines. The company unifies drug discovery and cell line development processes, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for ABSI?

Absci Corporation presents a compelling investment thesis centered on its integrated drug creation platform and its potential to accelerate biologic drug discovery. With a market capitalization of $1.57B, Absci operates in the high-growth biotechnology sector. Key value drivers include the company's ability to secure partnerships with established pharmaceutical companies and generate revenue through licensing and milestone payments. The company's high beta of 2.13 suggests significant market volatility. Growth catalysts include the advancement of partnered drug candidates through clinical trials and the expansion of its platform capabilities. However, the company's negative profit margin of -7306.4% and gross margin of -1336.5% indicate significant financial challenges. Investors should carefully consider the company's ability to achieve profitability and manage its cash burn rate. The company's success hinges on its ability to demonstrate the value of its integrated platform and secure additional partnerships.

Based on FMP financials and quantitative analysis

ABSI Key Highlights

Market Cap of $1.57B reflects investor valuation of Absci's drug discovery platform and potential for future growth.

• Profit Margin of -7306.4% indicates significant ongoing investment in research and development, typical for early-stage biotech companies.
• Gross Margin of -1336.5% highlights the cost-intensive nature of Absci's drug discovery and cell line development processes.
• Beta of 2.13 suggests that Absci's stock price is more volatile than the overall market, reflecting the high-risk, high-reward nature of biotechnology investments.
• No Dividend indicates that Absci is reinvesting all earnings back into the company to fund growth initiatives.

Who Are ABSI's Competitors?

ABSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABSI's Key Strengths?

Integrated drug creation platform.

• Expertise in cell line development.
• Partnerships with pharmaceutical companies.
• Focus on biologic drug candidates.

What Are ABSI's Weaknesses?

Negative profit and gross margins.

• Reliance on partnerships for revenue.
• Limited number of proprietary drug candidates.
• High beta indicates stock volatility.

What Could Drive ABSI Stock Higher?

Clinical trial results for partnered drug candidates.

• Expansion of partnerships with pharmaceutical companies.
• Development of new platform capabilities.
• Regulatory approvals for drug candidates.

What Are the Key Risks for ABSI?

Negative return on equity (-63.6%) — the business is not currently generating profit on shareholder capital.

• Failure of partnered drug candidates in clinical trials.
• Regulatory delays and hurdles.
• Competition from established pharmaceutical companies.
• Economic downturn affecting R&D spending.

What Are the Growth Opportunities for ABSI?

• Expansion of Partnerships: Absci can drive growth by expanding its partnerships with pharmaceutical companies. By securing additional partnerships and licensing agreements, Absci can generate revenue through upfront payments, milestone payments, and royalties. This strategy allows Absci to leverage its drug creation platform to develop a diverse pipeline of biologic drug candidates. A key to success will be demonstrating the platform's ability to accelerate drug discovery and reduce development costs.
• Advancement of Drug Candidates: The advancement of partnered drug candidates through clinical trials represents a significant growth opportunity for Absci. Each successful clinical trial milestone can trigger substantial payments from its partners. Absci's ability to support its partners in navigating the complex regulatory landscape and achieving positive clinical outcomes will be critical to realizing this growth opportunity. Positive clinical data can also enhance Absci's reputation and attract new partnerships.
• Expansion of Platform Capabilities: Absci can further enhance its growth prospects by expanding the capabilities of its integrated drug creation platform. This could involve incorporating new technologies, such as artificial intelligence and machine learning, to improve the efficiency and accuracy of drug discovery. By investing in platform innovation, Absci can differentiate itself from competitors and attract partners seeking cutting-edge drug discovery solutions. This also includes expanding into new therapeutic areas.
• Geographic Expansion: Absci can pursue geographic expansion to tap into new markets and diversify its revenue streams. The global biotechnology market is growing rapidly in emerging economies, such as China and India. By establishing a presence in these markets, Absci can access a larger pool of potential partners and customers. This expansion could involve establishing strategic alliances with local companies or setting up its own research and development facilities. Adapting its platform to meet the specific needs of these markets will be crucial for success.
• Development of Proprietary Drug Candidates: While Absci's current business model focuses on partnering with other companies, it could also explore the development of its own proprietary drug candidates. This would allow Absci to capture a greater share of the value created by its drug discovery platform. By developing its own pipeline of drug candidates, Absci can potentially generate significant revenue through direct sales and licensing agreements. This strategy would require significant investment in clinical trials and regulatory approvals.

What Are ABSI's Competitive Advantages?

• Integrated drug creation platform streamlines drug discovery.
• Proprietary technology accelerates biologic development.
• Partnerships with established pharmaceutical companies.
• Expertise in cell line development and optimization.

What Does ABSI Do?

Founded in 2011 and headquartered in Vancouver, Washington, Absci Corporation operates as a drug and target discovery company. It distinguishes itself by offering biologic drug candidates and production cell lines to partners, primarily within the United States. Absci's core innovation lies in its integrated drug creation platform, which streamlines the traditionally separate processes of drug discovery and cell line development into a unified workflow. This integration aims to accelerate the creation of biologics, potentially reducing development timelines and improving the efficiency of drug discovery. Absci's business model centers on partnering with other pharmaceutical and biotechnology companies, providing them with the tools and resources necessary to develop novel biologic therapies. By focusing on the early stages of drug development, Absci aims to capture value through licensing agreements, research collaborations, and potential milestone payments as its partners advance drug candidates through clinical trials and regulatory approval. The company's strategic focus on integrating drug discovery and cell line development positions it as a key player in the evolving landscape of biologic drug development.

What Products and Services Does ABSI Offer?

• Provides biologic drug candidates for pharmaceutical companies.
• Offers production cell lines to streamline drug manufacturing.
• Utilizes an integrated drug creation platform to unify drug discovery.
• Accelerates the development of novel biologic therapies.
• Partners with companies to advance drug candidates through clinical trials.
• Offers solutions for target discovery to identify new drug targets.

How Does ABSI Make Money?

• Partnerships with pharmaceutical and biotechnology companies.
• Revenue generation through licensing agreements.
• Milestone payments as partners advance drug candidates.
• Royalties on sales of approved drugs.

What Industry Does ABSI Operate In?

Absci Corporation operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. Absci's integrated drug creation platform positions it to capitalize on the growing demand for novel biologic therapies. However, the company faces competition from established pharmaceutical companies, specialized biotechnology firms like Erasca, Inc. (ERAS), and academic research institutions. Success in this industry requires a combination of scientific expertise, technological innovation, and strategic partnerships.

Who Are ABSI's Key Customers?

• Pharmaceutical companies seeking novel drug candidates.
• Biotechnology companies developing biologic therapies.
• Research institutions involved in drug discovery.
• Companies looking to outsource cell line development.

Wall Street analysts project Absci Corporation revenue of about $5.7M for fiscal 2026, with EPS near $-0.75. The estimate reflects 8 contributing analysts.

Quarterly Financial Performance: Absci Corporation

Revenue for Absci Corporation came in at $318K during Q2 2026, a 47.9% improvement versus the preceding quarter. The company recorded a net loss of $33.2M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ABSI averaged $-0.20 in diluted EPS.

ABSI Valuation & Market Position

With a $1.57B market cap, Absci Corporation sits in the small-cap segment of the market. Relative to its peer group, ABSI's quantitative score of 21/100 is below the peer average of 80/100.

Return on equity for Absci Corporation stands at -63.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.

Absci Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 38.60 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Absci Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, US. The company is led by CEO Sean McClain. ABSI has traded publicly since 2021.

ABSI Financials

ABSI Latest News

ABSI Analyst Consensus

ABSI MoonshotScore

What Investors Ask About Absci Corporation (ABSI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources